Darolutamide
Nubeqa (darolutamide) is a small molecule pharmaceutical. Darolutamide was first approved as Nubeqa on 2019-07-30. It has been approved in Europe to treat castration-resistant prostatic neoplasms. The pharmaceutical is active against androgen receptor. Nubeqa's patent is valid until 2036-01-28 (FDA).
Trade Name | Nubeqa |
---|---|
Common Name | Darolutamide |
Indication | castration-resistant prostatic neoplasms |
Drug Class | Non-steroid antiandrogens |